Here is the reality of BC's life sciences sector: the province excels at discovery but has historically struggled with the next phase. For decades, researchers at UBC and affiliated institutes have generated world-class pre-clinical work. However, the resulting therapies—including cell and gene treatments and biologics—have frequently been licensed to U.S. or European manufacturers, who then capture the commercial upside. The science remains in BC, but the economic value often leaves.

That dynamic is shifting. A cluster of biotech and cell-therapy companies anchored along UBC's Wesbrook corridor is investing in Good Manufacturing Practice (GMP) facility buildouts. This regulated, audit-ready infrastructure is required to produce therapies for human clinical trials and, ultimately, commercial sale. It is capital-intensive, technically demanding work. Facility construction costs typically run between $50 million and $200 million CAD depending on the modality, with cell and gene therapy facilities sitting at the higher end of that range. For a sector that has historically struggled to attract growth capital, these are significant commitments.

The scale of what is at stake is substantial. BC Life Sciences, the industry association, reports more than 16,000 employees across approximately 1,100 companies in the province—a cluster large enough to matter regionally, but one that has historically punched below its weight on commercialization. The firms now building GMP capacity are betting that the next phase of value creation will happen in BC, not in San Diego or Basel.

Why GMP Is the Bottleneck

GMP certification is the regulatory prerequisite for producing investigational therapies that enter human bodies. Without a GMP facility, there is no clinical trial, no regulatory submission, and no commercial product. For a company developing a novel cell therapy, the choice of where to manufacture is effectively the choice of where to commercialize. Licensing manufacturing to a contract development and manufacturing organization (CDMO) in the United States is a legitimate path, but it shifts significant leverage and margin to a third party.

AdMare BioInnovations—formerly known as the Centre for Drug Research and Development (CDRD)—has long served as a bridge institution, helping translate academic discoveries into development candidates. While valuable for early-stage work, that infrastructure was not designed to absorb the manufacturing demands of a sector moving toward clinical-stage programs. The gap between what AdMare can support and what a Phase II or Phase III program requires is precisely where BC companies have historically been forced to look offshore.

Genome BC's commercialization pipeline reports have flagged this structural constraint for several years. The issue is not the quality of BC science, but the absence of the downstream infrastructure required to convert that science into a product.

Who Is Building

The most visible buildout activity is concentrated in cell and gene therapy, where BC possesses scientific depth and where manufacturing complexity creates a competitive moat. Autologous cell therapies, which require patient-specific manufacturing runs, demand facilities designed around cleanroom flexibility and rigorous chain-of-custody protocols.

Several companies in the Wesbrook and broader Metro Vancouver corridor are at various stages of facility development. Timelines are long; a purpose-built GMP facility typically requires three to five years from design to first GMP batch, accounting for construction, equipment qualification, process validation, and regulatory inspection. Companies that initiated planning in 2022 and 2023 are now approaching the point where capital commitments become irreversible.

The Federal Money Is There—Mostly Unused

The capital environment for these buildouts is more supportive than at any point in BC's biotech history, though the funding is not flowing as efficiently as it could. The federal Strategic Innovation Fund has allocated over $2 billion nationally to life sciences since 2020, a post-pandemic commitment driven by the lesson that Canada lacked domestic biomanufacturing capacity during the COVID-19 vaccine rollout.

The National Research Council's Industrial Research Assistance Program (IRAP) has been an active funder of pre-commercial development, and the Canadian Institutes of Health Research has directed substantial funding to BC-based research programs. However, the transition from research grant to manufacturing capital involves different federal programs—such as the Strategic Innovation Fund and the Canada Biomedical Research Fund—that require more sophisticated applications than many BC biotechs have historically pursued.

This underutilization is partly a capacity issue. Writing a $75-million federal funding application requires grant-writing expertise, government-relations infrastructure, and the organizational maturity to manage a multi-year relationship. Early-stage biotechs often lack these resources. Consequently, the companies most likely to access federal manufacturing capital are those that have already scaled past Series B, creating a timing mismatch.

The Investment Case

For venture and growth capital, the GMP manufacturing story represents an inflection point, though the risk profile requires caution. Companies that successfully build GMP-certified facilities in BC will hold a structural advantage: proprietary manufacturing capability, regulatory credibility, and the ability to run clinical programs without depending on external CDMOs. This creates a durable moat, but it requires significant capital to sustain.

The risk-adjusted opportunity is strongest for growth-stage investors who can evaluate companies with existing pre-clinical or early clinical data, a credible manufacturing design, and a realistic federal funding plan. Pure seed-stage bets on GMP buildouts carry a different risk profile, as capital requirements dwarf typical seed check sizes and timelines extend well beyond standard venture fund horizons.

Invest Vancouver's life sciences sector profile has positioned the region as a target for international capital, and there is genuine interest from U.S. and European growth funds in BC's cell and gene therapy cluster. The question remains whether local capital—including BC's venture ecosystem, the BDC, and provincial pension funds—will move with enough conviction to anchor syndicates before U.S. lead investors extract the governance terms that accompany large-scale financing.

The Window Is Narrow

The global cell and gene therapy manufacturing landscape is not standing still. U.S. CDMOs are expanding aggressively, and the UK and Australia have made national-level commitments to domestic biomanufacturing. Canada's share of global cell and gene therapy clinical trials remains modest relative to peer nations, a gap that reflects the current manufacturing constraint.

The companies building GMP facilities in BC today are making a five-year bet. If they execute—and if federal and provincial capital flows into the right programs—the Wesbrook corridor could look meaningfully different by 2030, boasting a cluster with genuine end-to-end capability. BC has the science to justify this evolution; the next two years will determine whether it builds the infrastructure to sustain it.